Detailed Narrative
Robust Q4 FY26 Performance Driven by Domestic Formulations
RPG Life Sciences delivered a strong Q4 FY26, with revenue from operations growing by 23.6% to INR 176.9 crores compared to INR 143.1 crores in Q4 FY25. EBITDA saw a significant increase of 48.0% to INR 45.2 crores, improving the margin from 21.4% to 25.6%. This performance was primarily driven by the domestic formulations segment, which grew by 18.2%, outpacing the Indian pharma market growth of 10.1% by 1.8 times. The company was recognized as the fourth fastest-growing pharma company among the top 50 in Q4 FY26.
FY26 Overview and API Business Recovery
For the full financial year FY26, the company reported an 8.3% growth in revenue, reaching INR 707.5 crores, despite the API business being disrupted for a significant part of the year due to a fire incident. The API segment, which contributes 14% of revenues, demonstrated a strong recovery in Q4 with revenues of INR 33.3 crores, reflecting a 144% growth in the quarter. Overall FY26 EBITDA stood at INR 172.7 crores, maintaining a healthy margin of 24.4%.
Growth Drivers: Volume, New Products, and Brand Strength
The domestic formulation growth was fueled by a robust volume increase of 9.8% in Q4 (compared to 1.1% market) and new product introductions contributing 5.1% (compared to 3.5% market). Key brands like Naprosyn continued to perform strongly, achieving 24% growth in Q4 and 15.6% for FY26, with a target to become an INR 100 crores brand. The immunosuppressant portfolio is also targeted to reach INR 100 crores, supported by therapy expansions and deeper doctor engagement.
Operational Excellence and Digital Transformation
The company has made significant strides in improving execution metrics, with sales force productivity increasing from INR 5.7 lakhs to INR 6.5 lakhs per rep per month. Specialty segment productivity improved from INR 13.2 lakhs to INR 16.7 lakhs. Digital tools and automation, including the proprietary RPGserv platform, are enhancing doctor engagement and field effectiveness, enabling more structured and data-led interactions with healthcare professionals.
International and API Segment Strategy
The international formulation segment, contributing 17% of revenues, faced temporary headwind📎s from inventory rationalization and regulatory delays but is expected to return to growth next year. The API segment, a key growth driver, is focused on expanding its product pipeline with 13 products and exploring new markets. The company is also pursuing CDMO opportunities, with 5 projects in the pipeline, 3 expected this year and 2 in FY28.
Capital Structure and Inorganic Growth Outlook
RPG Life Sciences maintains a strong balance sheet with a cash surplus of approximately INR 275 crores, despite investing over INR 140 crores in capex over the last 4-5 years for modernization and expansion. The company holds an ICRA A+ rating with a stable outlook. Management is actively looking for inorganic growth opportunities in both formulations and API businesses, emphasizing prudent and value-accretive acquisitions to strengthen its domestic and international presence.